An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.

CONCLUSION: Entospletinib monotherapy at 800 mg twice daily demonstrated limited activity in patients with advanced, relapsed DLBCL.
PMID: 29934062 [PubMed - as supplied by publisher]

Source: Clinical Lymphoma and Myeloma - June 6, 2018 Category: Cancer & Oncology Authors: Burke JM, Shustov A, Essell J, Patel-Donnelly D, Yang J, Chen R, Ye W, Shi W, Assouline S, Sharman J Tags: Clin Lymphoma Myeloma Leuk Source Type: research